Phase
Condition
Bacterial Infections
Treatment
Ciprofloxacin
Placebo (microcrystalline cellulose)
Wound management
Clinical Study ID
Ages > 18 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients greater or equal to 18 years of age.
Bitten by a cat.
Location of bite is the hand and/or forearm (distal to elbow).
Presenting <24 hours following a cat bite to the hand/forearm.
English speaking
Exclusion
Exclusion Criteria:
- Patients who present with active local or systemic infections
Purulent drainage from the cat bite
Redness AND swelling at the location of the cat bite
Having a fever >100.4° F or >38° C)-Received antibiotics within the past 30 days
Received antibiotics within the past 30 days
Patients unwilling to take study medication
Patients unwilling to attend scheduled follow-up evaluations or complete study forms
Pregnant Women
Type I hypersensitivity reaction to any of the study interventions
Immunocompromised patients (primary and secondary immunodeficiencies) Primary
Autoimmune Lymphoproliferative Syndrome (ALPS)
Autoimmune Polyglandular Syndrome type 1 (APS-1)
B-cell Expansion with Nuclear factor kappa-light-chain-enhancer of activated B cellsand T-cell Anergy (BENTA) Disease
Caspase Eight Deficiency State (CEDS)
Caspase Recruitment Domain Family Member 9 (CARD9) Deficiency and Other Syndromes ofSusceptibility to Candidiasis
Cartilage-hair hypoplasia
Chédiak-Higashi syndrome
Chronic Granulomatous Disease (CGD)
Common Variable Immunodeficiency (CVID)
Complement Deficiencies
Congenital Neutropenia Syndromes
Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) Deficiency
Cyclic neutropenia
DiGeorge syndrome
Dedicator Of Cytokinesis 8 (DOCK8) Deficiency
GATA-binding protein 2 (GATA2) Deficiency
Glycosylation Disorders with Immunodeficiency
Hyper-Immunoglobulin E Syndromes (HIES)
Hyper-Immunoglobulin M Syndromes
Interferon Gamma, Interleukin 12 and Interleukin 23 Deficiencies
Leukocyte Adhesion Deficiency (LAD) Types 1 and 2
Lipopolysaccharide Responsive Beige-Like Anchor Protein (LRBA) Deficiency
Phosphatidylinositol 3-kinase (PI3-Kinase) Disease
Phospholipase C gamma 2 (PLCG2) associated Antibody Deficiency and ImmuneDysregulation (PLAID)
Severe Combined Immunodeficiency (SCID)
Selective Immunoglobulin A (IgA) deficiency
Signal transducer and activator of transcription 3 (STAT3) Dominant-Negative Disease
STAT3 Gain-of-Function Disease
Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Wiskott-Aldrich Syndrome (WAS)
X-Linked Agammaglobulinemia (XLA)
X-Linked Lymphoproliferative Disease (XLP)
X-linked magnesium transporter 1 (MAGT1) deficiency with increased susceptibility toEpstein-Barr virus (EBV) infection and N-linked glycosylation defect (XMEN) Disease
Zeta-associated protein 70 (ZAP-70) deficiency
Secondary
Malnutrition
Uncontrolled Diabetes mellitus
Chronic uremia
Genetic syndromes: trisomy 21
Immunomodulatory, immunosuppressive drug therapy: corticosteroids, calcineurininhibitors, cytotoxic agents
Systemic lupus erythematosus
Malignancy
Active radiation therapy
Bone marrow ablation
Infectious diseases: human immunodeficiency virus (HIV) infection, Hepatitis
Additional Primary and secondary immunodeficiencies can be found at the following link.
https://www.merckmanuals.com/professional/immunology-allergic-disorders/immunodeficiency- disorders/overview-of-immunodeficiency-disorders
Study Design
Study Description
Connect with a study center
University of Missouri
Columbia, Missouri 65212
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.